

27 May 2024

Mernova's Strong Progress Continues

Highlights:

- **Additional product development activities in addition to those previously announced for new edibles, vapes and dabbers products**
- **Agreements made with contract growers to supplement existing capacity given strong demand**
- **Q2 confirmed purchase orders of \$1.56m to date, highlighting ongoing strength of Ritual brand**
- **Purchase orders follow unaudited Q1 revenues of \$1.75m and FY23 full year revenues of \$6.9m**

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that its wholly owned Canadian subsidiary, Mernova, continues to make strong operational progress. In recent weeks, Mernova has finalised product development activities across a variety of new products.

- Edibles
 - Sour Lemon Raspberry gummies, 100% THC, 5mg THC/unit, pack of two gummies
 - Sour Mango Orange gummies, 1:1 THC:CBD, 5mg THC and 5mg CBD per unit, pack of two gummies
- Vapes
 - New flavour – Valley Apple Crisp, 1g vape
 - New flavour – Blueberry Grunt, 1g vape
- Dabbers
 - Black Mamba and Sugarb Bomb punch pipette products, ranging from 83% to 88% THC

Additionally, Mernova has reached agreements with two contract growing companies to supply additional cannabis material to supplement supply given currently strong demand. Muise Cannabis will supply the Company with Lemon Haze flower (a strain that Mernova already produces) and Culture Des Sommets will supply a new cultivar, Blue Pave, which is a highly touted high THC indica strain which the Company will market to existing markets. As Mernova's reputation continues to grow in the market, it continues to innovate with new products and supply opportunities to capitalise on demand.

During Q2 to date, Mernova has received purchase orders for \$1.56m (C\$1.41m at current C\$ to A\$ of 1.10) of product. This strong performance follows unaudited Q1 revenues of \$1.75m, and FY23 revenues of \$6.9m.

Management commentary:

CEO and Managing Director, Mr William Lay said: *"Mernova has developed into a stable, material revenue generating business unit for ME1. On the back of this success, we are excited that the team is exploring new product launches and contract growers to continue capitalising on demand."*

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the CEO and MD of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.